Advertisement

Clinical Implications of the STAR*D Trial

  • A. John Rush
  • Shailesh (Bobby) Jain
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 250)

Abstract

This chapter provides a synopsis of the clinically relevant findings derived from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study and selected ancillary studies appended to the primary trial. The chapter describes the participants, their recruitment and treatment, and the study design, primary outcomes, and clinically informative results. In particular, the chapter describes acute phase response and remission rates from each of the five treatment steps which entail antidepressant monotherapies and combinations, and psychotherapy alone or in combination with an antidepressant. In addition, longer-term outcomes beyond the 12 week acute trial are described for each treatment step. The treatment challenges described include patient retention and relapse, and longer-term follow-up. The chapter discusses the use of measurement-based care for delivering high-quality care, describes “treatment-resistant” depression and discusses its implications for clinical practice, and discusses the contributions of STAR*D to patient-oriented research and patient care.

Keywords

Depression Pharmacotherapy Practical clinical trial Sequence treatment alternatives to relieve depression Treatment resistance Treatment steps 

Notes

Acknowledgments

The author appreciates the editorial assistance of Jon Kilner and the secretarial and administrative assistance of Corrie Brown.

Disclosures

Dr. Rush has received consulting fees, Akili Inc., Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Emmes Corp, LivaNova, MindLinc, Sunovion, Taj Medical, Takeda, USA; royalties, Guilford Publications, University of Texas Southwestern Medical Center at Dallas (for the Inventory of Depressive Symptoms and its derivatives); and speaking fees, LivaNova.

Dr. Rush is named as co-inventor on two patents:
  1. 1.

    US Patent No. 7795033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS

     
  2. 2.

    US Patent No. 7906283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S

     

Dr. Jain has no disclosures to report.

References

  1. Agency for Healthcare Research and Quality (2017) Technology assessment program: definition of treatment-resistant depression in the Medicare population. https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/drafts-for-review/trd-draft.pdf. Accessed 28 Aug 2017
  2. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ (2012) Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 125:342–348CrossRefGoogle Scholar
  3. Blier P (2001) Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 62:7–11PubMedGoogle Scholar
  4. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al (2003) Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26:457–494CrossRefGoogle Scholar
  5. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ et al (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161–1172CrossRefGoogle Scholar
  6. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN et al (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165:342–351CrossRefGoogle Scholar
  7. Gaynes BN, Rush AJ, Trivedi M, Wisniewski SR, Balasubramani GK, Spencer DC et al (2005) A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry 27:87–96CrossRefGoogle Scholar
  8. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani G, McGrath PJ et al (2008) Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med 23:551–560CrossRefGoogle Scholar
  9. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ (2009) What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60:1439–1445CrossRefGoogle Scholar
  10. Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, Rush AJ (1998) Texas medication algorithm project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 59:345–351CrossRefGoogle Scholar
  11. Guidi J, Fava GA, Fava M, Papakostas GI (2011) Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med 41:321–331CrossRefGoogle Scholar
  12. Guo T, Xiang YT, Xiao L, Hu CQ, Chiu HF, Ungvari GS et al (2015) Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry 172:1004–1013CrossRefGoogle Scholar
  13. Hedayati S, Gregg L, Carmody T, Jain N, Toups M, Rush AJ et al (2017) Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the cast randomized clinical trial. JAMA 318:1876–1890CrossRefGoogle Scholar
  14. Jha MK, Minhajuddin A, Gadad BS, Greer T, Granneman B, Soyombo A et al (2017) Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 78:105–113CrossRefGoogle Scholar
  15. Jha MK, Teer RB, Minhajuddi AT, Greer TL, Rush AJ, Trivedi MH (2017a) Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. Neuropsychiatr Dis Treat 13:803–813CrossRefGoogle Scholar
  16. Jha MK, Minhajuddi AT, Greer TL, Carmody TC, Rush AJ, Trivedi MH (2017b) Early improvement in psychosocial function predicts longer-term symptomatic remission in depressed patients. PLoS One 11(12):e0167901.  https://doi.org/10.1371/journal.pone.0167901 CrossRefGoogle Scholar
  17. Lavori PW, Dawson R, Rush AJ (2000) Flexible treatment strategies in chronic disease: clinical and research implications. Biol Psychiatry 48:605–614CrossRefGoogle Scholar
  18. Lavori PW, Rush AJ, Wisniewski SR, Alpert J, Fava M, Kupfer DJ et al (2001) Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 50:792–801CrossRefGoogle Scholar
  19. Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16:622–626CrossRefGoogle Scholar
  20. Marcus SM, Kerber KB, Rush AJ, Wisniewski SR, Nierenberg A, Balasubramani GK et al (2008) Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the sequenced treatment alternatives to relieve depression study. Compr Psychiatry 49:238–246CrossRefGoogle Scholar
  21. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA et al (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531–1541CrossRefGoogle Scholar
  22. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ et al (1998) The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 59:608–619CrossRefGoogle Scholar
  23. Mundt JC, Marks IM, Shear MK, Greist JH (2002) The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry 180:461–464CrossRefGoogle Scholar
  24. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ et al (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519–1530CrossRefGoogle Scholar
  25. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ et al (2007) Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 164:1181–1188CrossRefGoogle Scholar
  26. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW (2007) Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 64:689–697CrossRefGoogle Scholar
  27. Perlis RH, Patrick A, Smoller JW, Wang PS (2009) When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34:2227–2236CrossRefGoogle Scholar
  28. Poirier MF, Boyer P (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 175:12–16CrossRefGoogle Scholar
  29. Quitkin FM, McGrath PJ, Stewart JW, Deliyannides D, Taylor BP, Davies CA, Klein DF (2005) Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiatry 66:670–676CrossRefGoogle Scholar
  30. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353–365CrossRefGoogle Scholar
  31. Rosenblat JD, Lee Y, McIntyre RS (2017) Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry 78:720–729CrossRefGoogle Scholar
  32. Rush AJ (2011) STAR-D: lessons learned and future implications. Depress Anxiety 28:521–524CrossRefGoogle Scholar
  33. Rush AJ (2015) Isn’t it about time to employ measurement-based care in practice? Am J Psychiatry 172:934–936CrossRefGoogle Scholar
  34. Rush AJ, Ibrahim HM (2018) A clinician’s perspective on biomarkers. Focus 16:124–134CrossRefGoogle Scholar
  35. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN et al (2003a) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583CrossRefGoogle Scholar
  36. Rush AJ, Crismon L, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH et al (2003b) Texas medication algorithm project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 64:357–369CrossRefGoogle Scholar
  37. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA et al (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142CrossRefGoogle Scholar
  38. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006a) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917CrossRefGoogle Scholar
  39. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E et al (2006b) Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 31:1841–1853CrossRefGoogle Scholar
  40. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006c) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242CrossRefGoogle Scholar
  41. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC et al (2006d) An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 59:493–501CrossRefGoogle Scholar
  42. Rush AJ, Kilner J, Fava M, Wisniewski SR, Warden D, Nierenberg AA et al (2008a) Clinically relevant findings from STAR* D. Psychiatr Ann 38(3):188–193CrossRefGoogle Scholar
  43. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M et al (2008b) Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 65:870–880CrossRefGoogle Scholar
  44. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, Nierenberg AA (2009) STAR*D revising conventional wisdom. CNS Drugs 23:627–647PubMedGoogle Scholar
  45. Rush AJ, Wisniewski SR, Zisook S, Fava M, Sung SC, Haley CL et al (2012) Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol Med 42:1131–1149CrossRefGoogle Scholar
  46. Sackeim HA (2001) The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62(Suppl 16):10–17PubMedGoogle Scholar
  47. Stahl SM (2000) Essential psychopharmacology: neuroscientific basis and practical applications. Cambridge University Press, CambridgeGoogle Scholar
  48. Thase ME, Rush AJ (1997) When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23–29PubMedGoogle Scholar
  49. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF et al (2007) Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 164:739–752CrossRefGoogle Scholar
  50. Trivedi MH, Kleiber BA (2001) Algorithm for the treatment of chronic depression. J Clin Psychiatry 62(Suppl 6):22–29PubMedGoogle Scholar
  51. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T et al (2004a) The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34:73–82CrossRefGoogle Scholar
  52. Trivedi MH, Kern JK, Grannemann BD, Altshuler KZ, Sunderajan P (2004b) A computerized clinical decision support system as a means of implementing depression guidelines. Psychiatr Serv 55:879–885CrossRefGoogle Scholar
  53. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ et al (2004c) Clinical results for patients with major depressive disorder in the Texas medication algorithm project. Arch Gen Psychiatry 61:669–680CrossRefGoogle Scholar
  54. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006a) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40CrossRefGoogle Scholar
  55. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D et al (2006b) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252CrossRefGoogle Scholar
  56. Trivedi MH, Rush AJ, Gaynes BN, Stewart JW, Wisniewski SR, Warden D et al (2007) Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 32:2479–2489CrossRefGoogle Scholar
  57. Uher R, Carver S, Power RA, Mors O, Maier W, Rietschel M et al (2012) Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med 42:2027–2035CrossRefGoogle Scholar
  58. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR (2007a) The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 9:449–459CrossRefGoogle Scholar
  59. Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN et al (2007b) Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 164:1189–1197CrossRefGoogle Scholar
  60. Warden D, Rush AJ, Wisniewski SR, Lesser IM, Kornstein SG, Balasubramani GK et al (2009) What predicts attrition in second step medication treatments for depression?: a STAR*D report. Int J Neuropsychopharmacol 12:459–473CrossRefGoogle Scholar
  61. Wisniewski SR, Rush AJ, Balasubramani G, Trivedi MH, Nierenberg AA et al (2006) Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 12:71–79CrossRefGoogle Scholar
  62. Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF et al (2009) Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 166:599–607CrossRefGoogle Scholar
  63. Young AS, Klap R, Sherbourne CD, Wells KB (2001) The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 58:55–61CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • A. John Rush
    • 1
    • 2
    • 3
  • Shailesh (Bobby) Jain
    • 4
  1. 1.Duke-National University of SingaporeSingaporeSingapore
  2. 2.Department of PsychiatryDuke Medical SchoolDurhamUSA
  3. 3.Deparment of PsychiatryTexas Tech University-Health Sciences CenterLubbockUSA
  4. 4.Department of PsychiatryTexas Tech University Health Sciences CenterLubbockUSA

Personalised recommendations